Last reviewed · How we verify
VLA1553 full dose
At a glance
| Generic name | VLA1553 full dose |
|---|---|
| Sponsor | Valneva Austria GmbH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children (PHASE3)
- A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VLA1553 full dose CI brief — competitive landscape report
- VLA1553 full dose updates RSS · CI watch RSS
- Valneva Austria GmbH portfolio CI